CAI
Caris Life Sciences Inc.

815
Mkt Cap
$7.53B
Volume
1.79M
52W High
$42.50
52W Low
$21.00
PE Ratio
-11.03
CAI Fundamentals
Price
$26.76
Prev Close
$26.54
Open
$26.16
50D MA
$28.20
Beta
-0.70
Avg. Volume
1.73M
EPS (Annual)
-$1.35
P/B
15.78
Loading...
Loading...
News
all
press releases
Can Caris Life Sciences,?Inc. (CAI) Climb 32.81% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 32.8% upside potential for Caris Life Sciences,?Inc. (CAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·5d ago
News Placeholder
More News
News Placeholder
Caris Life Sciences, Inc.'s Lock-Up Period To End on December 15th (NASDAQ:CAI)
Caris Life Sciences' (NASDAQ:CAI - Get Free Report) lock-up period is set to expire on Monday, December 15th. Caris Life Sciences had issued 23,529,412 shares in its IPO on June 18th. The total size...
MarketBeat·5d ago
News Placeholder
Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium
Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium PR Newswire...
PR Newswire·9d ago
News Placeholder
The Caris Precision Oncology Alliance Welcomes UAMS Winthrop P. Rockefeller Cancer Institute
The Caris Precision Oncology Alliance Welcomes UAMS Winthrop P. Rockefeller Cancer Institute The Caris Precision Oncology Alliance Welcomes UAMS Winthrop P. Rockefeller Cancer Institute PR Newswire...
PR Newswire·11d ago
News Placeholder
Caris Precision Oncology Alliance Fellows Forum Welcomes 2025/2026 Class
Caris Precision Oncology Alliance Fellows Forum Welcomes 2025/2026 Class Caris Precision Oncology Alliance Fellows Forum Welcomes 2025/2026 Class PR Newswire IRVING, Texas, Nov. 21, 2025 IRVING...
PR Newswire·22d ago
News Placeholder
Caris Life Sciences to Attend Q4 2025 Investor Conferences
Caris Life Sciences to Attend Q4 2025 Investor Conferences Caris Life Sciences to Attend Q4 2025 Investor Conferences PR Newswire IRVING, Texas, Nov. 17, 2025 IRVING, Texas, Nov. 17, 2025...
PR Newswire·26d ago
News Placeholder
Caris Data Validates TET2 Clonal Hematopoiesis as a Biomarker for Enhanced Immunotherapy Response
Caris Data Validates TET2 Clonal Hematopoiesis as a Biomarker for Enhanced Immunotherapy Response Caris Data Validates TET2 Clonal Hematopoiesis as a Biomarker for Enhanced Immunotherapy Response PR...
PR Newswire·1mo ago
News Placeholder
Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025
Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025 Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025 PR Newswire IRVING...
PR Newswire·2mo ago
News Placeholder
Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025
Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025 Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025 PR Newswire IRVING, Texas, Oct. 14, 2025 IRVING, Texas, Oct...
PR Newswire·2mo ago
News Placeholder
TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape
Tempus AI's PurIST test secures clinical validation, helping personalize treatment choices for advanced pancreatic cancer patients.
Zacks·3mo ago

Latest CAI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.